FDA approves new Alzheimer's treatment from Eli Lilly
FDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Alexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19. Previously, he was a campaign reporter for CBS News based out of Las Vegas, where he was raised. He covered presidential, Senate and House candidates for the 2020 election cycle in Arizona, California, Nevada and New Mexico. He has also worked in Washington for "Face the Nation" and in New York for the "CBS Evening News." Tin graduated from Columbia University in 2017 with a bachelor's degree in political science.
FDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
The CDC says it is too early to say if this year's summer COVID-19 surge has arrived.
The FDA said its study better simulated how commercial milk processing kills the bird flu virus, H5N1.
Here's CBS News' fact check of statements made by Biden and Trump during the first 2024 presidential debate.
The LB.1 variant makes up close to 1 in 5 new COVID cases, the CDC estimates.
A key COVID trend in the West is near "high" levels, the CDC says, and the new variant LB.1 is gaining ground.
The CDC looked at emergency medical services data from 27 states.
An experiment found "small but detectable" amounts of infectious H5N1 virus in milk after it was pasteurized for 15 seconds.
The two genetic changes to H1N1 could cut the effectiveness of the main flu antiviral doctors turn to.
While raw milk can't be sold over state lines, some states permit sales within their borders.
The RSV vaccine by GSK was previously approved only for adults 60 and older.
The strain is "very, very similar" to the JN.1 variant from earlier this year.
The FDA said "additional review" and court cases led it to roll back the ban.
FDA advisers cited a variety of concerns with the trials submitted by Lykos Therapeutics as part of the application.
The hearing on COVID-19 marked Dr. Anthony Fauci's first public appearance on Capitol Hill since leaving government in 2022.